No Data
No Data
BioMarin Pharmaceutical (NASDAQ:BMRN) Adds US$792m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 28%
Earnings Preview: BMRN to Report Financial Results Post-market on May 01
BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying
Oppenheimer Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $98
Why BioMarin Pharmaceutical (BMRN) Is a Top Growth Stock for the Long-Term
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET